BLU · Bellus Health
Acquired Company
GSK completed the acquisition of BELLUS Health on 6/28/2023 by way of a plan of arrangement, acquiring all outstanding common shares for US$14.75 per share in cash, representing a total equity value of US$2.0 billion.
BELLUS Health is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders. The Company's product candidate, BLU-5937, is being developed for the treatment of chronic cough and chronic pruritus.
275 Armand-Frappier Blvd, Quebec, H7V 4A7, Canada
Pharmaceutical Preparation Manufacturing
Manufacturing
Market Cap
N/A
52 Wk Range
N/A - N/A
Previous Close
$14.74
Open
$14.74
Volume
3,449,256
Day Range
$14.74 - $14.75
Enterprise Value
N/A
Cash
N/A
Avg Qtr Burn
N/A
Insider Ownership
10.26%
Institutional Own.
90.41%
Qtr Updated
Jun 30th 2024